Remepy’s app-drug combo heads for Phase III on mid-stage Parkinson’s win

Levodopa plus Remepy’s digital health app, DopApp, offered significant activities of daily living and motor function benefits. Levodopa plus Remepy’s digital health app, DopApp, offered significant activities of daily living and motor function benefits. Remepy’s Hybridopa offered statistically significant improvements in motor and non-motor symptoms over placebo in a Phase IIa Parkinson’s study. Credit: PeopleImages / Shutterstock.com. Remepy is taking its hybrid Parkinson’s therapy, Hybridopa, to Phase III, after the blended app-drug approach offered motor and non-motor outcome improvements in a mid-stage pilot study. In the three-week Phase IIa trial, Remepy randomised 41 patients aged 45-80 with Parkinson’s disease to…

Source: Clinical Trials Arena